RSSCategory: Health Policy

What is ‘right to try,’ and could it help? – Viewpoint

What is ‘right to try,’ and could it help? – Viewpoint

Ultimately, we believe right to try is poised to give the Trump administration a political win on a popular public policy but will do little to change the status quo for terminally ill patients. Some opponents say, if anything, it could give terminally ill patients false hope for new access to drugs they already can obtain through existing FDA policy.

February 12, 2018 | By | Reply More
Upsurge of suburban poor discover health care’s nowhere land

Upsurge of suburban poor discover health care’s nowhere land

Suburbs in the United States, often perceived as enclaves of the affluent, are home to nearly 17 million Americans who live in poverty — more than in cities or rural areas — and growing demand for care strains the capacity of suburban health services to provide for them.

February 9, 2018 | By | Reply More
Why Amazon and friends’ plan could be a major disrupter of health care system

Why Amazon and friends’ plan could be a major disrupter of health care system

While the companies’ leaders say what the changes that must happen in the healthcare delivery sector, the implied the assumption is that doctors and hospitals will adapt to this new world, holding down their costs, making prices more transparent, and innovating in their physical and electronic delivery of care.

February 4, 2018 | By | Reply More
Unnecessary medical care is more common than you think

Unnecessary medical care is more common than you think

A study in Washington state found that in a single year more than 600,000 patients underwent treatment they didn’t need, at an estimated cost of $282 million. “Do no harm” should include the cost of care, too, the report author says.

February 1, 2018 | By | Reply More
As states target high drug prices, pharma targets state lawmakers

As states target high drug prices, pharma targets state lawmakers

With federal officials seemingly unwilling or unable to come up with legislation to control skyrocketing drug prices, that task is increasingly moving to the states. But so is pharma muscle and money opposing the measures, regulatory disclosures and corporate filings from the last two years show.

February 1, 2018 | By | Reply More
Expert advice for the corporate titans taking on health care

Expert advice for the corporate titans taking on health care

Amazon, Berkshire Hathaway, and JPMorgan Chase & Co.’s plans to join forces to address the high costs of employee health care has stirred the health policy pot. KHN asked a variety of health policy experts their thoughts on this venture, and what advice they would offer these CEOs as they go forward.

January 31, 2018 | By | Reply More
As Trump attacks the federal health law, some states try to shore it up

As Trump attacks the federal health law, some states try to shore it up

This year, a handful of Democratic-led states are gearing up to curb further rate hikes caused by changes implemented by the Trump administration by enacting laws and adopting insurance regulations designed to shore up the traditional insurance industry and restore parts of the ACA, known as Obamacare.

January 26, 2018 | By | Reply More
Big pharma greets hundreds of ex-federal workers at the ‘revolving door’

Big pharma greets hundreds of ex-federal workers at the ‘revolving door’

Nearly 340 former congressional staffers now work for pharmaceutical companies or their lobbying firms. On the flip side, the analysis showed, more than a dozen former drug industry employees now have jobs on Capitol Hill — often on committees that handle health care policy.

January 25, 2018 | By | Reply More
States face costly conundrum: How to treat inmates with hepatitis C

States face costly conundrum: How to treat inmates with hepatitis C

In 2013, Gilead Sciences introduced Sovaldi, the first of a new generation of drugs called direct-acting antivirals that can cure hepatitis C and with fewer side effects than the previous treatments. But the excitement was dampened by the drug’s price. A full course of treatment carried an $84,000 price tag.

January 24, 2018 | By | Reply More
US life expectancy just dropped for the second year in a row. Let’s stop the trend now – Viewpoint

US life expectancy just dropped for the second year in a row. Let’s stop the trend now – Viewpoint

Life expectancy has fallen for the second time in two years – from a high of 78.9 years in 2014 to 78.6 years in 2016. It fell for men and women, whites, blacks and Hispanics. Statistics show that thousands were preventable, premature deaths.

January 22, 2018 | By | Reply More